Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis

Key facts

Sponsor

Dompé Farmaceutici S.p.A

Principal Investigator

Brad Kligman, MD

SightMD, New York, New York

Intervention

OXERVATE® 0.002%(drug)

Eligibility

18 years · All sexes

Timeline

2024 – 2024

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Neurotrophic keratopathy

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT07502378
  Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency
  University of South Florida
• RECRUITINGPHASE1, PHASE2NCT06999733
  A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
  Krystal Biotech, Inc.
• RECRUITINGPHASE2NCT06975748
  A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
  Staidson (Beijing) Biopharmaceuticals Co., Ltd
• RECRUITINGPHASE4NCT06964269
  Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
  Toyos Clinic
• ACTIVE NOT RECRUITINGPHASE1NCT06597422
  A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects
  Staidson (Beijing) Biopharmaceuticals Co., Ltd
• RECRUITINGPHASE2NCT05927428
  Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
  BRIM Biotechnology Inc.
• RECRUITINGPHASE3NCT05555589
  Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
  ReGenTree, LLC
• ACTIVE NOT RECRUITINGPHASE4NCT06947850
  DOMPE -MT Neurotrophic Keratitis
  Toyos Clinic

See all trials for Neurotrophic keratopathy →